Rhythm Pharmaceuticals
Tracked across 9 events · 55 articles · First seen Feb 14, 2026 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Rhythm Pharmaceuticals is the defendant in a class action lawsuit, accused of making false and misleading statements regarding its CELLECTRA device and INO-3107 Biologics License Application.
Apr 01, 2026 · 7 articles
Business
Impact: Rhythm Pharmaceuticals is facing a federal securities lawsuit alleging that its officers and directors breached fiduciary duties by misrepresenting or failing to disclose critical information regarding its CELLECTRA device and INO-3107 BLA submission.
Jun 01, 2026 · 6 articles
Business
Impact: INOVIO is raising $20M through a dilutive public offering, which may pressure its stock price but provides capital for its DNA medicine programs.
Jul 29, 2026 · 6 articles
Regulatory
Impact: Rhythm Pharmaceuticals is the developer and sponsor of OMCAZIO. The tentative approval is a major regulatory milestone that advances its oncology pipeline and commercial prospects.
Jul 31, 2026 · 6 articles
Business
Impact: Lotus secures exclusive commercialization rights in eight Asian markets and U.S. rights via Alvogen, expanding its biosimilar portfolio and global reach.
Aug 21, 2026 · 6 articles
Tech
Impact: Partner on ReFeel; this event highlights PBC Biomed's network but has limited direct impact.
Aug 12, 2026 · 6 articles
Business
Impact: Rhythm Pharmaceuticals is noted as a company where Brosgart currently serves on the board; no direct impact.
Aug 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Rhythm Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard